Core Viewpoint - The market for weight loss drugs is experiencing significant growth, highlighted by the recent IPO of Silverno Pharmaceuticals, which saw a massive surge in stock price and market interest in related companies [1][4][7]. Group 1: Market Performance - Silverno Pharmaceuticals' stock price increased by 206% on its first trading day, achieving a market capitalization exceeding HKD 26 billion, making it one of the hottest IPOs of 2025 [1][4]. - Other companies in the weight loss drug sector, such as Pag BioPharma and Song Li Pharmaceutical, also saw substantial stock price increases of 32.45% and 13.72%, respectively [1][5][7]. - In the A-share market, companies like Borui Pharmaceutical and Changshan Pharmaceutical have doubled their stock prices this year, with Borui Pharmaceutical increasing by 280% [10][12]. Group 2: Company Highlights - Silverno Pharmaceuticals focuses on innovative therapies for diabetes and metabolic diseases, with its core product, Isupatide α, recently approved for treating type 2 diabetes in China [4]. - Pag BioPharma is developing multiple GLP-1 related drugs, with its lead product PB-119 showing promise in the weight loss sector [5]. - Borui Pharmaceutical's BGM0504 injection, a dual-target GLP-1/GIP drug, has completed Phase III clinical trials and is expected to be a significant player in the weight management market [12]. Group 3: Industry Outlook - The global obesity issue is driving the demand for weight loss drugs, positioning this sector as a "golden track" in the pharmaceutical industry [7]. - Analysts predict that the GLP-1 drug market could exceed USD 150 billion by 2030, with several domestic companies poised to become billion-dollar enterprises [14]. - The commercialization of domestic weight loss drugs is anticipated to enhance competition, with companies that have strong sales capabilities and advanced R&D likely to lead the market [14].

Core Insights - The market for weight loss drugs is gaining significant attention, with companies like Silverno Pharmaceuticals and others experiencing substantial stock price increases [1][5][11] - Silverno Pharmaceuticals has seen a remarkable IPO performance, with a 5341.66 times oversubscription and a market capitalization exceeding HKD 26 billion [3] - The overall performance of weight loss-related stocks in both Hong Kong and A-share markets has been strong, with several companies reporting over 100% gains this year [5][8] Company Performance - Silverno Pharmaceuticals' core product, Isupaglutide α, has generated revenue of approximately CNY 38.14 million within four months of its launch in China [3] - Other companies like Pag Biopharma and Songli Pharmaceutical have also seen significant stock price increases, with Pag Biopharma rising 32.45% and Songli Pharmaceutical increasing by 13.72% [4][5] - In the A-share market, companies such as Borui Pharmaceutical and Changshan Pharmaceutical have reported gains of 280% and over 100%, respectively [8][10] Market Trends - The global obesity issue is driving the demand for weight loss drugs, positioning this sector as a "golden track" in the pharmaceutical industry [5] - Analysts predict that the GLP-1 drug market could exceed USD 150 billion by 2030, highlighting the potential for domestic oral weight loss drugs [11] - Companies with strong research and sales capabilities are expected to dominate the commercialization of weight loss drugs, with a focus on those with advanced R&D progress [11]

Core Viewpoint - The recent IPO of Silver诺医药-B has generated significant interest and profit in the market, driven by its innovative weight-loss drug, I苏帕格鲁肽α, which is set to become the first domestically developed long-acting GLP-1 receptor agonist in China [1][2][9]. Company Overview - Silver诺医药-B (02591.HK) opened at 72 HKD per share, a 285% increase from its issue price of 18.68 HKD, and closed at 55.9 HKD, reflecting a 199.25% rise, with a total market capitalization of 25.54 billion HKD [1][2]. - The company has incurred losses of 12.04 billion CNY over the past three years, with projected losses of 2.96 billion CNY in 2022, 7.33 billion CNY in 2023, and 1.75 billion CNY in 2024 [8][13]. Product Pipeline - The core product, I苏帕格鲁肽α, is aimed at treating type 2 diabetes and is expected to be approved by the National Medical Products Administration (NMPA) in January 2025 [2][9]. - The company is also developing new indications for obesity and related metabolic diseases, with IND approval for phase II trials received in July 2023 [4][5]. Market Context - The global obesity issue is severe, with over 400 million overweight and obese individuals in China alone, highlighting a significant market opportunity for weight-loss drugs [5]. - The GLP-1 therapy market is becoming increasingly competitive, with several other companies, including 九源基因 and 派格生物, also entering the Hong Kong stock market [2][14]. Investment and Financing - Silver诺医药 has completed four rounds of financing, raising a total of 1.514 billion CNY, with notable investors including KIP, 光大控股, and 中金资本 [10][12][13]. - The company’s valuation reached 4.65 billion CNY after its latest financing round, but it faces challenges due to significant operational losses [13]. Competitive Landscape - The GLP-1 market is attracting attention from wealthy investors and companies, with various players like 联邦制药 and 丽珠集团 also developing similar products [14][16]. - The competition is intensifying, with established companies having stronger financial backing compared to Silver诺医药, which relies on its academic and research strengths [19].

格隆汇8月14日丨联邦制药(03933.HK)公告，董事会将于2025年8月28日(星期四)举行会议，其中包括考 虑及批准公司及其附属公司截至2025年6月30日止6个月的中期业绩，及宣派中期股息(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 聯邦制藥國際控股有限公司（「本公司」）董事會（「董事會」）謹此公佈，董事會將 於二零二五年八月二十八日（星期四）舉行會議，其中包括考慮及批准本公司及其附屬 公司截至二零二五年六月三十日止六個月的中期業績，及宣派中期股息（如有）。 承董事會命 聯邦制藥國際控股有限公司 公司秘書 梁永康 香港，二零二五年八月十四日 於本公告日期，董事會成員包括執行董事蔡海山先生、梁永康先生、蔡紹哲女士、方煜 平先生、鄒鮮紅女士及朱蘇燕女士；以及獨立非執行董事張品文先生、宋敏教授及傅秋 實博士。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 (於開曼群島成立之有限公司) (股份代號: 3933) 董事會召開日期 ...

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.02%, with notable stock performances including Jingtai Holdings (02228) up 7.38% and Fosun Pharma (02196) up 6.00% [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.52%, reaching a latest price of 0.97 yuan, with a trading volume of 240.45 million yuan and a turnover rate of 0.62% [3] - Jingtai Holdings announced an expected comprehensive income of no less than 500 million yuan for the six months ending June 30, 2025, representing an increase of at least 387% compared to the same period in 2024 [3] Group 2 - The Hong Kong Innovative Drug Selection ETF reached a new high in scale at 385 million yuan and a new high in shares at 399 million [4] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 22.93 million yuan, totaling 42.28 million yuan [4] - The ETF's management fee is 0.50% and the custody fee is 0.10%, which are among the lowest in comparable funds [5] Group 3 - The HSSCPB index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5] - The top ten weighted stocks in the HSSCPB index account for 78.05% of the total index weight, including companies like BeiGene (06160) and WuXi Biologics (02269) [5]

Group 1 - Xinda Biologics announced the official launch of its dual receptor agonist, Masitide, for weight management, which is the first GCG/GLP-1 dual receptor agonist approved for long-term weight control in adults in China [1] - Clinical data shows that Masitide can achieve a weight reduction of 21%, over 80% reduction in liver fat content, and significant improvements in cardiovascular and metabolic indicators [1] - The GLP-1 weight loss drug market has seen significant growth, with Novo Nordisk's semaglutide generating $16.5 billion in revenue and Eli Lilly's tirzepatide generating $14.7 billion in the first half of 2025 [1] Group 2 - The trend in GLP-1 weight loss drug development is shifting towards multi-target, long-acting, and oral formulations, with many domestic innovative pharmaceutical companies actively participating [2] - The popularity of GLP-1 drugs has been fueled by endorsements from high-profile individuals, leading to increased public interest and demand for these medications [3] - The market for GLP-1 drugs in China is estimated to be between 40 billion to 50 billion yuan, with significant potential for generic drugs as original patents expire [5] Group 3 - The competitive landscape for GLP-1 weight loss drugs is evolving, with various products entering the market, and companies need to adapt their commercialization strategies to succeed [6][9] - Regulatory requirements for GLP-1 products in China are stringent, necessitating large-scale clinical trials, which poses challenges for many companies [7] - Partnerships and business development (BD) opportunities are emerging as companies seek to expand their market presence internationally, with notable agreements already in place [8]

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 重新提交 公司名稱: 聯邦制藥國際控股有限公司 II. 已發行股份及/或庫存股份變動 呈交日期: 2025年8月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03933 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,800,000,000 | HKD | | 0.01 | HKD | | 38,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,800,000,000 | HKD | | 0.01 | HKD | | 3 ...

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index (HSSCPB) decreased by 1.63% as of August 8, 2025, with mixed performance among constituent stocks [3] - The top-performing stocks included CSPC Pharmaceutical Group (up 4.44%), United Laboratories (up 3.29%), and Kangji Medical Holdings (up 1.38%), while the worst performers were Hutchison China MediTech (down 15.70%), Zai Lab (down 10.86%), and BeiGene (down 6.47%) [3] - The Hong Kong Stock Connect Innovative Drug Selected ETF (520690) fell by 1.64%, with the latest price at 0.96 yuan [3] Group 2 - The pharmaceutical and biotechnology sector received a policy boost with the release of measures to support high-quality development of innovative drugs in July 2025, leading to a significant increase of 13.93% in the sector [4] - The latest share count for the Hong Kong Stock Connect Innovative Drug Selected ETF reached 360 million, a new high since its inception [4] - Recent net inflows into the ETF amounted to 4.92 million yuan, with a total of 32.45 million yuan net inflow over the last five trading days [4] Group 3 - The top ten weighted stocks in the HSSCPB index accounted for 78.03% of the total index weight, including companies like BeiGene, Innovent Biologics, and WuXi Biologics [6]

Group 1 - The Hong Kong pharmaceutical sector is under pressure, with the Hong Kong pharmaceutical ETF (159718.SZ) experiencing a decline of 1.18% despite a net subscription of 9 million in half a day [1] - Among the constituent stocks, CSPC Pharmaceutical (01093) led the gains with an increase of 3.93%, while Hutchison China MediTech (00013) fell sharply by 15.42% after its earnings report [1] - Hutchison China MediTech reported a revenue of $2.777 billion for H1 2025, a decrease of 9%, with oncology product revenue down by 22% to $0.99 billion [1] Group 2 - The Hong Kong pharmaceutical ETF focuses on 18 A-share biotech companies, including BeiGene, WuXi Biologics, CSPC Pharmaceutical, and 3SBio, benefiting from global innovation drug development [2] - The combination of policy benefits, overseas expansion, and profit realization is driving the revaluation of Hong Kong pharmaceutical stocks [2] - Weak U.S. economic and employment data may accelerate the Federal Reserve's interest rate cuts, enhancing global liquidity and benefiting technology stocks, suggesting a focus on the Hong Kong pharmaceutical ETF (159718.SZ) and its linked funds [2]